JRSM > Volume 97, Number 5 > Pp. 226-229

This Article Figures Only Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greene, O. Articles by Durrington, P. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK

Owen Greene BSc     Paul Durrington FRCP FMedSci  

University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
E-mail: pdurrington{at}man.ac.uk

Life expectancy in familial hypercholesterolaemia (FH) has been greatly improved by the advent of statin therapy. In the UK, however, these agents are not licensed for use in children. We approached 169 physicians responsible for lipid clinics for information on their practice in young patients, and valid responses were received from 54%.

A typical lipid clinic has only 3.5 patients aged under 16 with FH. In boys aged 10-15 years 65% of physicians were prepared to treat with bile acid sequestrants but only 23% with statins. There was greater reluctance to treat in girls of the same age, corresponding figures being 52% and 12%.

Despite the efficacy of statins in reducing low-density-lipoprotein cholesterol, these agents are little used in children with FH. Their safety and clinical efficacy should be assessed by a randomized double-blind trial.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Durrington NICE guidance for identification and treatment of familial hypercholesterolaemia: Commentary 2 Heart, April 1, 2009; 95(7): 589 - 591. [Full Text] [PDF]